G. Gebauer et al., IMMULITE (R) OM-MA assay: A useful diagnostic tool in patients with benignand malignant ovarian tumors, ANTICANC R, 19(4A), 1999, pp. 2535-2536
Measurement of CA125 is well established in the diagnosis and follow-up of
ovarian cancer. CA125 determination is usually performed with the monoclona
l antibodies OC125 and Mil. For the IMMULITE(R) OM-MA chemoluminsence assay
(DPC Biermann, Bad Nauheim, Germany) the monoclonal antibody OV185 is used
. We analysed CA125 serum concentrations of patients with benign and malign
ant ovarian tumors with the IMMULITE(R) OM-MA assay by defining a cut-off a
t 90% specificity level. Sera of 130 patients with benign and 119 patients
with malignant ovarian tumors at different FIGO stages were analysed. By ca
lculating a cut-off of 46 U/ml, in 87 ovarian cancer patients, elevated CA1
25 concentrations were detected (78% sensitivity). There were no significan
t differences between CA125 concentrations of tumors of different histologi
cal type. The measurement of CA125 by IMMULITE(R) OM-MA is a simple and sen
sitive procedure.